Patients with stage II and IIIB non-small cell lung cancer (NSCLC) with an EGFR mutation had better outcomes when treated ...

Study examines treatment options for those with operable non-small cell lung cancer, the leading cause of cancer deaths ...

Patients with oligometastatic lung cancer may live longer with surgery, but experts stress the need for multidisciplinary ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease ...

Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

Adding immunotherapy to chemotherapy before surgery for patients with operable non-small cell lung cancer (NSCLC) - the ...

Prof Patrick Forde of the Trinity St James’s Cancer Institute presented the findings at the latest meeting of the American ...

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

New blood tests can detect cancer recurrence earlier than traditional scans, potentially giving doctors and patients crucial ...